Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus.
Joseph A LewnardLouis F FriesIksung ChoJanice ChenRamanan LaxminarayanPublished in: Proceedings of the National Academy of Sciences of the United States of America (2022)
SignificanceStrategies to reduce consumption of antimicrobial drugs are needed to contain the growing burden of antimicrobial resistance. Respiratory syncytial virus (RSV) is a prominent cause of upper and lower respiratory tract infections, as a single agent and in conjunction with bacterial pathogens, and may thus contribute to the burden of both inappropriately treated viral infections and appropriately treated polymicrobial infections involving bacteria. In a double-blind, randomized, placebo-controlled trial, administering an RSV vaccine to pregnant mothers reduced antimicrobial prescribing among their infants by 12.9% over the first 3 mo of life. Our findings implicate RSV as an important contributor to antimicrobial exposure among infants and demonstrate that this exposure is preventable by use of effective maternal vaccines against RSV.
Keyphrases
- respiratory syncytial virus
- antimicrobial resistance
- staphylococcus aureus
- respiratory tract
- primary care
- double blind
- adverse drug
- birth weight
- open label
- sars cov
- risk factors
- randomized controlled trial
- pregnant women
- placebo controlled
- phase iii
- emergency department
- study protocol
- gram negative
- newly diagnosed
- physical activity
- weight gain
- weight loss